Australia's most trusted
source of pharma news
Posted 30 September 2025 PM
Makers of the P2Y12 inhibitor clopidogrel will be hoping for a change in clinical guidelines and a big leap in sales after a study showed it to be a more effective blood thinner than aspirin.
The meta-analysis of seven randomised trials, involving almost 29,000 patients, compared clopidogrel monotherapy with aspirin monotherapy in patients with established coronary artery disease (CAD) who had discontinued or never started dual antiplatelet therapy (a P2Y12 inhibitor in combination with aspirin).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.